small molecule

BALVERSA

ERDAFITINIB

Loss of exclusivityFebruary 2038latest FDA-listed patent expiry

CompanyJanssen Biotech →See this company's full patent-cliff portfolio

Drug detail

Brand name	BALVERSA
Active ingredient	ERDAFITINIB
Strength	5MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	April 2019
Marketing status	RX

Listed patents

Patent	Expires	Type
11077106	February 2038	use U-3808
10478494	August 2036	use U-3902
10898482	February 2036	product
11684620	February 2036	use U-3806
12037644	October 2035	use U-3972
9902714	March 2035	product
8895601	April 2033	substance, product
9464071	April 2031	use U-3805

Regulatory exclusivity

Code	Expires
I-930	January 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Janssen Biotech